Drug Efficacy Testing in Preclinical Studies

HuaTeng Bio delivers end-to-end preclinical efficacy solutions for oncology drug development, combining validated in vivo and in vitro models to quantify therapeutic potential. Our tumor-specific platforms include:

•     Patient-derived xenograft (PDX) models with matched clinical biomarker profiling
•     Syngeneic models for immuno-oncology candidate screening
•     3D tumor spheroid/Organoid co-cultures mimicking tumor microenvironment
•     Orthotopic implantation for metastasis evaluation

Integrated with advanced imaging (IVIS, micro-CT) and longitudinal biomarker monitoring, we generate IND-ready data packages demonstrating dose-dependent tumor growth inhibition (TGI) and survival benefit. All studies comply with FDA/EMA guidelines for translational relevance.

HuaTeng Bio provides specialized in vivo and in vitro efficacy evaluation for cardiovascular drug candidates, utilizing clinically predictive models to validate therapeutic mechanisms and hemodynamic outcomes. Our tailored approaches include:

• Myocardial infarction models (surgical LAD ligation & ischemic-reperfusion injury)
• Hypertension/dyslipidemia models (SHR rats, ApoE-/- mice with atherogenic diets)
• Ex vivo aortic ring assays for vasodilation/constriction quantification
• 3D cardiac microtissue platforms with electrophysiological monitoring

Integrated telemetry-based hemodynamic profiling and biomarker analysis (BNP, troponin, oxidative stress markers) generate translational data on:

• Dose-dependent blood pressure reduction
• Plaque area regression in atherosclerosis models
• Improved cardiac output in heart failure paradigms
• Arrhythmia risk mitigation in proarrhythmia models

All studies adhere to ICH S7A and EMA/CVMP guidelines, with GLP-compliant reporting for global submission readiness.

HuaTeng Bio provides validated in vivo and in vitro efficacy testing for metabolic disorder therapeutics, targeting diabetes, obesity, NAFLD/NASH, and dyslipidemia. Our species-flexible platforms (rodents, rabbits, mini-pigs) deliver clinically translatable data through:

Disease-specific models:

• Diet-induced obesity (DIO) mice with hyperinsulinemic-euglycemic clamps
• STZ/HFD-induced type 2 diabetes in rats
• Methionine-choline deficient (MCD) diet NASH models
• Genetic models (Zucker fa/fa rats, db/db mice)

Functional metabolic profiling:

• Oral glucose tolerance tests (OGTT) with continuous glucose monitoring
• Hepatic lipidomics via MRI-PDFF and histopathological scoring
• Adipose tissue browning quantification (UCP1 immunohistochemistry)
• Gut microbiome modulation analysis (16S rRNA sequencing)

HuaTeng Bio delivers specialized in vivo and in vitro efficacy evaluation for central nervous system (CNS) therapeutics, targeting neurodegenerative diseases, psychiatric disorders, and chronic pain. Our translational platforms combine behavioral, electrophysiological, and molecular analyses across species (rodents, rabbits, non-human primates) to validate therapeutic mechanisms.

Disease-specific models:

• Traumatic Brain Injury Model
• Cerebral Hemorrhage Model
• Migraine Model
• Depression Model
• Parkinson's Disease Model
• Sleep Deprivation Model
• Spinal Cord Injury Model
• Pituitary Glandectomy Model
• Alzheimer's Disease Model
• Rat Middle Cerebral Artery Occlusion (MCAO) Model
• Complete Transection of Spinal Cord Injury Model
• Brain Edema Model / Cerebrospinal Fluid Hydrocephalus Model
• Rat Mild Hepatic Encephalopathy Model
• Rat Temporal Lobe Epilepsy (TLE) Model
• PTZ-Induced Chronic Epilepsy Model in Rats
• Middle Cerebral Artery Ischemia-Reperfusion Model
• Rat Craniocerebral Injury Electrical Stimulation Model

HuaTeng Bio offers comprehensive preclinical CRO services to evaluate drug efficacy for respiratory diseases through validated in vitro and in vivo models. Our in vitro platforms utilize cutting-edge cell-based assays, including primary airway epithelial cultures and 3D air-liquid interface (ALI) systems, to assess anti-inflammatory, bronchodilatory, or antiviral effects. For in vivo studies, we employ rodent models of asthma, COPD, pulmonary fibrosis, and acute lung injury, measuring lung function parameters, inflammatory biomarkers, and histopathological endpoints. All protocols adhere to global regulatory standards (e.g., OECD, FDA) and are tailored to replicate human disease pathophysiology, ensuring translatable results for IND submissions.